Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE SOS1 INHIBITOR (SYH2038) OBTAINS CLINICAL TRIAL APPROVAL

VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE SOS1 INHIBITOR (SYH2038) OBTAINS CLINICAL TRIAL APPROVAL

November 29, 2023

a231127_00.png

Previous: VOLUNTARY ANNOUNCEMENT - SYH2053 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL

Next: CSPC Signs Cooperation Agreement with AstraZeneca for Joint Confirmatory Research Targeting Lung Cancer

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat